Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 30, 2020March 30, 2020

Canada Clears EHP-101, Possible Cannabidiol-derived Treatment

News

The active ingredient in EHP-101 — known as VCE-004.8, derived from synthetic cannabidiol — is not classified as a controlled substance under Canada’s Controlled Drug and Substance Act (CDSA), the potential ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

March 4, 2020March 4, 2020

CHMP Favors EU Approval of Ofev to Preserve Lung Function in SSc-ILD

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ofev (nintedanib) to preserve lung function in people with systemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD) in the ... Read more

February 28, 2020February 28, 2020

Inhibiting Key Protein May Ease Lung Scarring in Systemic Scleroderma, Study Suggests

News

Inhibiting a protein known as KLHL42 may ease lung fibrosis (scarring) associated with systemic scleroderma (SSc), according to a recent study. The findings were published in an article, “Kelch-like ... Read more

January 24, 2020January 29, 2020

Tests with Hand Function Tasks Better for Assessing Scleroderma Progression, Treatment Response, Study Finds

News

Women with scleroderma take longer to perform daily living tasks, especially those that require hand strength and gripping objects, such as moving things between shelves, a new study found. ... Read more

December 2, 2019December 2, 2019

Health Canada Approves Ofev to Help Preserve Lung Health in People with SSc-ILD

News

Health Canada has approved Ofev (nintedanib) as a treatment to slow the decline of pulmonary function in people with scleroderma-associated interstitial lung disease (SSc-ILD). The approval makes Ofev, by Boehringer Ingelheim, the first treatment ... Read more

November 4, 2019November 4, 2019

Skin Lesions Develop Soon After Onset of Raynaud’s Phenomenon, 10-year Follow-up Study Reports

News

Most people with scleroderma develop skin lesions within one year after the onset of Raynaud’s phenomenon (RP), a condition in which the fingers and toes feel numb, prickly, and ... Read more

October 16, 2019October 16, 2019

One-Year Cytoxan Treatment Improves Lung Function in Scleroderma-ILD Patients, Trials Show

News

Treatment for one year with the immunosuppressant Cytoxan (cyclophosphamide) improves lung function in scleroderma patients with interstitial lung disease (SSc-ILD) — but these benefits wear off after stopping treatment, data from ... Read more

August 26, 2019August 26, 2019

Newer EUSTAR-AI Scale Ably Predicts Short-term Risk of SSc Progression, Study Finds

News

The European Scleroderma Trials and Research Group (EUSTAR) revised activity index scale, known as EUSTAR-AI, is the best tool for predicting the short-term risk of disease progression and severe ... Read more

August 12, 2019August 12, 2019

Sarcopenia May Affect up to 55% of Patients with SSc, Study Suggests

News

Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found ... Read more

Pin It on Pinterest